A retrospective study of efficacy of preexposure prophylaxis with AZD7442 (tixagevimab-cilgavimab) against Sars-Cov-2 variants in patients with chronic lymphocytic leukemia
Latest Information Update: 23 Jan 2023
At a glance
- Drugs Cilgavimab/tixagevimab (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 23 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition